Spinal Implants and Surgery Devices Market - Insights on Scope and Growing Demands 2025

According to the new market research report spinal implants and surgery devices market is projected to reach USD 13.8 billion by 2025 from USD 10.3 billion in 2019, at a CAGR of 5.0%.

Advancements in spine surgery technologies, increasing incidence of spinal disorders, the launch of advanced bone grafting products, and the increasing adoption of minimally invasive spine surgeries are driving the growth of the spinal implants and surgery devices market. However, the high cost of spinal surgery and uncertainties surrounding reimbursement are expected to restrain the growth of this market during the forecast period.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=712

Based on product, the spinal implants and surgery devices market is segmented into thoracic fusion and lumbar fusion devices, cervical fusion devices, spine biologics, non-fusion devices, vertebral compression fracture treatment devices, spinal decompression devices, and spine bone stimulators. The thoracic fusion and lumbar fusion devices segment accounted for the largest share of the spinal implants and surgical devices market. This can be attributed to the increasing preference for minimally invasive spine procedures; rising incidence and prevalence of spine degenerative diseases such as spondylolisthesis, degenerative scoliosis, and spinal stenosis; and technological innovations in minimally invasive interbody fusion devices.

Based on technology, the spinal implants and surgery devices market is segmented into spinal fusion and fixation, vertebral compression fracture treatment, motion preservation/non-fusion, and spinal decompression technologies. The spinal fusion and fixation technologies segment accounted for the largest share of the market in 2019. This can be attributed to the rising incidence of target diseases with the rising geriatric population across the globe, growing number of spinal fusion procedures, and technological advancements in spinal fusion techniques and bone grafting procedures.

Based on the type of surgery, the spinal implants and surgery devices market is segmented into open and minimally invasive surgeries. The open surgeries segment accounted for the largest share of the spinal implants and surgery devices market in 2019. The large share of this segment can be attributed to the increasing preference for open spine surgeries among medical professionals, rising incidence of spinal deformities, and technological advancements in spinal fusion surgeries.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=712

The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. This can be attributed to the improving healthcare infrastructure, rising awareness, improving reimbursement scenario, and the growing insurance coverage in several APAC countries.

Ambulatory EHR Market Insights on Scope and Growing Demands 2021

According to research the research report “Ambulatory EHR Market is expected to reach USD 5.20 billion by 2021 from USD 3.92 billion in 2016, at a CAGR of 5.8% in the next five years (2016 to 2021).

A combination of bottom-up and top-down approaches was used to calculate the market sizes and growth rates of the market and its subsegments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

The report provides an overall understanding of the market. In this report, the market is segmented on the basis of application, delivery mode, practice size, end user, and region. On the basis of application, the market is segmented into practice management, patient management, e-prescribing, referral management, population health management, decision support, and health analytics. The practice management segment accounted for the largest share of the ambulatory EHR market in 2016.

Download Free Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=235617627

On the basis of delivery mode, the market is segmented into cloud-based solutions and on-premises solutions.
On the basis of practice size, the market is categorized into large practices, small-to-medium practices, and solo practices.
On the basis of end user, the market is divided into hospital-owned ambulatory centers and independent centers.
On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

Geographic analysis reveals North America accounted for the largest share of the market in 2016, owing to the federal mandates, increasing geriatric population, collaboration between stakeholders, the need to curtail healthcare costs, payment deductions driving the adoption of EHR, conferences and workshops to raise awareness in the U.S., growing efforts to enhance healthcare delivery, and the adoption of digital recordkeeping in Canada.

Some of the major players in the market include Cerner Corporation (U.S.), McKesson Corporation (U.S.), Allscripts Healthcare Solutions, Inc. (U.S.), Epic Systems Corporation (U.S.), eClinicalWorks (U.S.), athenahealth, Inc. (U.S.), NextGen Healthcare Information Systems, LLC (U.S.), Practice Fusion, Inc. (U.S.), eMDs, Inc. (U.S.), Amazing Charts, LLC (U.S.), GE Healthcare (U.S.), and Greenway Health, LLC (U.S.).

qPCR Reagents Market - New Growth Opportunities for Market Leaders

According to research report qPCR reagents market is poised to reach $1,893.9 Million by 2020 From USD 1,307.0 Million in 2015, growing at a CAGR of 7.7%, during 2015 to 2020.

Over the last decade, the qPCR industry has witnessed significant technological advancement & robust product development. These advancements are transforming the field of forensic & disease diagnostic application of qPCR; leading to more effective & timely treatment of chronic and infectious diseases (such as cancer, AIDS, influenza, and hepatitis).

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102087588

North America and a major part of Europe are mature markets for qPCR reagents. However, emerging regions such as Asia-Pacific (including China and India) are expected to become new revenue-generating pockets in the market over the next five years. The North American qPCR reagents market is expected to hold the largest share during the forecast period owing to high penetration of qPCR technologies among key end users, increasing public & private funding to expand the application base of qPCR, ongoing product advancements in the field of qPCR reagents, and continuous reduction in the average cost of genome sequencing.

The Asia-Pacific region is expected to witness the fastest market growth for qPCR reagents during the forecast period. Growth in this market is fueled by increasing penetration of global life sciences companies in this region, rising focus of governments on increasing the awareness about gene-based disease diagnosis and treatment, growing public and private support to develop novel qPCR technologies, and advancing cancer research in Japan.

Due to the significant growth opportunities offered by emerging countries, a number of players operating in the market are focusing on expansion in these regions. For instance, in November, 2012, Thermo Fisher Scientific established a manufacturing facility in Suzhou (China) with an investment of USD 20 Million. The facility is involved in the manufacturing of life science equipment and consumables (including qPCR reagents) and caters to the life science & pharmaceutical industry. Similarly, in August, 2012, Bio-Rad Laboratories established the Digital Biology Center (U.S.) to develop innovative PCR products based on the company’s droplet partitioning technology.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=102087588

The qPCR reagents that are used for pathogen detection, forensic applications, and disease diagnosis offer a promising future to market aspirants focusing on expanding their revenue base in the market. Their growth is propelled by the increasing R&D to develop and commercialize novel products, growing market adoption of gene-based diagnostic techniques, and rising emphasis on effective & early disease diagnosis across major markets. Several companies such as Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., and Takara Bio are investing in these high-growth markets to gain higher profits and to increase their shares in the global qPCR reagents market.

Coronary Stent Market | Growth, Trends, and Forecast 2021

According to the research report the coronary stent market is expected to reach USD 10.31 billion by 2021 from USD 7.16 billion in 2016, at a CAGR of 7.6% from 2016 to 2021. Major factors driving the growth of this market include technological advancements, increasing number of percutaneous coronary intervention (PCI) procedures, rising burden of CAD, increasing demand for minimally invasive procedures, and rising geriatric population.

Download Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=77411272

Major Market Developments:
• In November 2016, Abbott received approval from the Ministry Of Health, Labor And Welfare (MHLW) (Japan) for its Absorb bioresorbable heart stent. This is the only dissolving heart stent used for the treatment of patients with coronary artery disease in Japan. This approval will help the company expand its presence in the Japanese market.
• In January 2016, Abbott acquired St. Jude Medical, Inc. (U.S.), a manufacturer of products for heart failure, atrial fibrillation, and cardiac rhythm management for USD 25 billion. The acquisition helped Abbott to strengthen its coronary intervention product offerings and increase its presence in the cardiovascular devices market
• In May 2016, Boston Scientific collaborated with Mayo Clinic (U.S.) to share intellectual property and speed the development of medical devices. This collaboration focuses on the development of medical technologies in the fields of interventional cardiology, heart rhythm management, endoscopy, neuromodulation, urology and pelvic health. This will help the company to strengthen its product offerings.
The coronary stent market is segmented based on type, material; mode of delivery, end user, and region.

Based on type, the coronary stent market is segmented into bare-metal stents, drug-eluting stents and bioabsorbable stents. The bioabsorbable stents segment is expected to grow at the highest CAGR during the forecast period. These stents help restore normal vasomotion, improve abnormal endothelial function, and lower the risk of complications such as thrombosis and inflammation. Such advantages are driving high growth in the bioabsorbable stents market.

Based on mode of delivery, the coronary stents market is segmented into balloon-expandable stents and self-expanding stents. The balloon-expandable stents segment is expected to grow at the highest CAGR during the forecast period due to factors such as increasing research activities to improve this technology, high utilization of these stents, and growing regulatory approvals for balloon-expandable stents.

Asia is expected to grow at a highest CAGR during the forecast period. Factors such as large population base, growing prevalence of cardiac diseases, rising adoption of advanced technologies, and low manufacturing costs in the region are expected to drive market growth in Asia. Moreover, the growing focus of major players in this region is expected to boost the coronary stents market in Asia.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=77411272

Key players in the Coronary Stent Market include Medtronic plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), Biosensors International Group, Ltd. (Singapore), BIOTRONIK SE & Co. KG (Germany), B. Braun Melsungen AG (Germany), TERUMO CORPORATION (Japan), STENTYS SA (France), MicroPort Scientific Corporation (China), Meril Life Sciences Pvt. Ltd. (India), Vascular Concepts (India), and Translumina GmbH (Germany).

Key players in this market are pursuing strategies such as product approvals; product launches and enhancements; partnerships, collaborations, and contracts; expansions; acquisitions; and certifications.

Gel Documentation Systems Market - Global Forecast to 2023

The Gel Documentation Systems Market is projected to grow from USD 258 million in 2018 to USD 304 million by 2023, at a CAGR of 3.3% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17162887

Growth in the gel imaging systems market is mainly driven by the increasing prevalence of infectious and chronic disease, and rising research & development expenditure in the pharmaceutical and biotechnology companies.

By product, the instruments segment is expected to grow at the highest rate during the forecast period in the gel documentation systems market

Based on product, the gel imaging systems market is segmented into three segments, namely, instruments, software, and accessories. The instruments segment is further divided into digital gel documentation instruments and gel documentation instruments. During the forecast period, the instruments segment is estimated to register the highest growth rate in the overall gel imaging systems market. This is mainly due to the increased R&D activities in the biotechnology and pharmaceutical industries.

Request for Reports Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=17162887

By end user, the academic and research institutes segment is expected to be the largest contributor to the gel documentation systems market in 2018

Based on end user, the gel imaging systems market is segmented into academic and research institutes; pharmaceutical & biotechnology companies; diagnostic laboratories. The academic and research institutes segment is estimated to account for the largest share of the overall market in 2018. This is primarily attributed to the increasing research activities on genomics and proteomics in research institutes and rising government funding in academic institutes.

Prosthetic Heart Valve Market | Industry Report 2017 - 2022

According to the new market research report Prosthetic Heart Valve Market is projected to reach USD 8.86 Billion by 2022 from USD 4.84 Billion in 2017, at a CAGR of 12.9% during the forecast period.
The key factors driving the growth of this market include the rising geriatric population and the subsequent growth in the prevalence of HVD, regulatory approvals for new and advanced prosthetic heart valves, increasing government funding for heart valve research, rising awareness about HVD, and favorable reimbursement scenario for prosthetic heart valves.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=245407958
Medtronic plc (Ireland), Edwards Lifesciences Corporation (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.), LivaNova PLC (U.K.), Symetis SA (Switzerland), Jenavalve Technology, Inc. (Germany), CryoLife, Inc. (U.S.), TTK Healthcare Limited (India), Colibri Heart Valve, LLC (U.S.), Lepu Medical Technology Co., Ltd. (China), and Braile Biomédica (Brazil) are the prominent players in the global prosthetic heart valves market.
The Transcatheter Heart Valves Segment Is Expected to Account for the Largest Share of the Prosthetic Heart Valves Market in 2017
Based on the type of valve, the prosthetic heart valves market is segmented into transcatheter heart valves, tissue heart valves, and mechanical heart valves. The transcatheter heart valves segment is expected to command the largest market share in 2017. The large share of this segment can be attributed to factors such as the rising prevalence of aortic stenosis, increasing pool of patients owing to approvals for extended valve indications, and technological advancements. The preference for transcatheter heart valves is expected to see high growth in the future as they are implanted through a minimally invasive procedure while the other valve types require open-heart surgery.
Request For Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=245407958
North America to Command the Largest Market Share in 2017
Based on region, the prosthetic heart valves market is divided into North America, Europe, Asia-Pacific, and the Rest of the World. In 2017, North America is expected to account for the largest share of the global market. Factors such as the rapid growth in the aging population and prevalence of valvular heart diseases, favorable reimbursement scenario, and rising product approvals for heart valves are contributing to the growth of the North American prosthetic heart valves market are driving the growth of the North American prosthetic heart valves market.

Clinical Alarm Management Market Major Players and Global Forecast 2023

The global clinical alarm management market is expected to reach USD 1,724 million by 2023 from an estimated USD 457 million in 2018, at a CAGR of 30.4%. The clinical alarm management market is rapidly emerging with many regional as well as international companies. In 2017, Koninklijke Philips (Netherlands) and Vocera Communications (US), held a share of approximately 70.0% of the clinical alarm management market.
The major clinical alarm management vendors include Koninklijke Philips (Netherlands), Vocera Communications (US), Ascom Holdings (Switzerland), Spok, Inc. (US), Bernoulli Enterprise (US), Connexall (Canada), Mobile Heartbeat (US), GE Healthcare (US), Capsule Technologie (US), and Masimo Corporation (US). These players have adopted various growth strategies, such as product launches and enhancements; acquisitions; expansions; and agreements, partnerships, mergers, and collaborations. Product launches and partnerships and have been the most dominating strategy adopted by major players from 2015 to 2018, which helped them to innovate on their offerings and broaden their customer base.

Download PDF brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=69939577
Koninklijke Philips dominated the global clinical alarm management market in 2017. The firm’s clinical alarm management solutions are designed to help caregivers manage alarms and reduce fatigue. Through these solutions the caregivers receive actionable notifications and communicate directly on a smartphone which enables workflow optimization, drives efficiency, and facilitates collaboration among staff. For instance, St. Antonius Hospital (the Netherlands) reduced irrelevant ICU alarms by 40% by utilizing Philips’ clinical alarm management solutions. The company focuses on inorganic growth strategies such as agreements, collaborations, and partnerships—to strengthen its presence in the clinical alarm management market. For instance, in November 2015, Philips entered into a partnership with Mackenzie Health (Canada) to enable Mackenzie Health to get early and ongoing access to Philips’ latest healthcare technology innovations, including systems interoperability, diagnostic imaging equipment utilization, radiology practice management, patient-centric design, and alarm management.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=69939577

Vocera Communications is one of the leading players in the clinical alarm management market. The firm has been in the market for about 18 years and offers a diversified range of solutions, including Vocera Alarm Management, Vocera Engage, and Vocera Collaboration Suite among others. Vocera strategically focuses on innovation, which is evident from its investments in R&D (USD 27.7 million (17.0% of sales) in 2017). The firm plans to further invest in R&D activities and improve its R&D capabilities to unlock additional synergies and growth opportunities. This helps the company to constantly develop innovative solutions such as Vocera Alarm Management and Vocera Engage.
Sales to the healthcare market accounted for 98.0%, 97.0% and 98.0% of its overall revenue for the years ended December 31, 2017, 2016, and 2015, respectively.

Sterility Testing Market –Top Key Players and Market Growth

According to the new market research report sterility testing market is expected to reach USD 941.0 Million by 2021 from USD 528.0 Million in 2016, at a CAGR of 12.3% from 2016 to 2021.
The growth of the sterility testing market can be attributed to the growth in the pharmaceutical and biotechnology industries, increase in the number of new drug launches, and increasing R&D in life science research.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=208866931

Major players in the sterility testing market include Merck KGaA (Germany), Charles River Laboratories International, Inc. (U.S.), bioMérieux SA (France), SGS S.A. (Switzerland), Sartorius AG (Germany), WuXi AppTec (China), Nelson Laboratories (U.S.), Danaher Corporation (U.S.), Pacific Biolabs (U.S.), Toxikon Corporation (U.S.), and Thermo Fisher Scientific, Inc. (U.S.).

Merck KGaA (Germany) dominated the sterility testing market in 2015. The company’s dominance in the market can be attributed to its robust product portfolio and strong geographic presence. The company focuses on organic as well as inorganic growth strategies for enhancing its market position. In September 2016, the company launched its Steritest Symbio Pump systems to enhance its product portfolio and increase its market presence. Furthermore, the company was focused on inorganic growth strategies. In November 2015, Merck KGaA acquired Sigma-Aldrich Corporation (U.S.); this acquisition helped the company strengthen its sterility testing product portfolio.

Charles River Laboratories International, Inc. (U.S.) held the second position in the sterility testing market in 2015. This can be attributed to the company’s strong sterility testing portfolio. The company adopted organic growth strategies such as mergers and acquisitions to boost its market share. In November 2015, Charles River acquired Celsis International Ltd. (U.S.). This acquisition helped the company to strengthen its microbial detection product portfolio. Also in November 2015, Charles River Laboratories acquired Oncotest GmbH (Germany), a global CRO dedicated to discovery services for oncology. This acquisition strengthened Charles River's portfolio of target discovery & validation services and in vivo pharmacology.

bioMérieux SA (France) held the third position in the sterility testing market in 2015. The company focuses on organic as well as inorganic growth strategies such as expansions and collaborations to enhance its market share. In March 2016, it entered into a distribution and co-development strategic partnership with Copan Italia S.p.A. (Italy). According to the terms of this agreement, bioMérieux SA and Copon will work together to distribute and develop solutions for microbiology laboratory automation and efficiency. Furthermore, the company was focused on organic growth strategies. In Octamer 2014, bioMérieux opened a new diagnostic testing facility in Isère, France. This facility enabled the company to develop new diagnostic solutions related to microbiology.

SGS S.A. (Switzerland) held the fourth position in the sterility testing market in 2015. The company adopted organic growth strategies such as expansions to boost its market share. In September 2016, SGS opened a new facility in Wiesbaden, Germany. The 500-m2 facility will provide extractables and leachables (E&L) testing to the pharmaceutical and related industries. This helped company to expand its quality control release testing capabilities at that facility. Also in December 2016, SGS acquired Quality Compliance Laboratories Inc. (U.S.). This acquisition helped the company to provide microbiological and analytical testing to pharmaceutical, nutraceutical, and cosmeceutical industries.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=208866931

Based on the analysis of strategic developments undertaken by market players between 2013 and 2016, the key strategies followed by most companies in the sterility testing market are expansions and acquisitions. Some of the leading players that adopted this strategy include bioMérieux SA (France), Merck KGaA (Germany), Nelson Laboratories (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Charles River Laboratories (U.S.), and WuXi AppTec (China).

Liquid Biopsy Market is projected to reach $2,047.9 Million By 2022

The global liquid biopsy market is projected to reach USD 2,047.9 million by 2022 from USD 715.7 million in 2017, at a CAGR of 23.4%. The liquid biopsy market is a consolidated market with a large number of companies offering liquid biopsy instruments and accessories. In 2016, QIAGEN N.V. (Netherlands), Roche Diagnostics (US), and Illumina, Inc. (US) dominated the liquid biopsy market.
QIAGEN is the leading player in the liquid biopsy market in 2016. The company is a global provider of sample-to-insight solutions that aids in the transformation of biological samples into molecular insights. The company operates through its two business segments, namely, instruments and consumables & related products. QIAGEN provides solutions to more than 500,000 customers globally, in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharma and biotech companies), and academia (life sciences research). The company operates in the liquid biopsy market through its molecular diagnostics and life science tools customer base segment.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350

Roche Diagnostics ranked second in the liquid biopsy market in 2016. Roche Diagnostics focuses on the discovery, manufacturing, and marketing of medical devices used to screen, diagnose, and monitor therapies. The company operates in the liquid biopsy market through its molecular diagnostics segment. The company geographically operates in Europe, the Middle East and Africa, North America, Asia Pacific, and Latin America.

Illumina ranked third in the liquid biopsy market in 2016. The company provides sequencing and array-based solutions for genetic analysis. The company develops, manufactures, and markets integrated systems and life science tools for the analysis of genetic variation and biological function.
The company operates in the liquid biopsy market through its spinoff company “GRAIL Inc.”
Some of the other players competing in this market are Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), Pathway Genomics Corporation (US), ANGLE plc (UK), Vortex Biosciences (US), Epic Sciences (US), Cynvenio Biosystems Inc. (US), Personal Genome Diagnostics, Inc. (US), MedGenome Inc. (US), Exosome Diagnostics (US), NeoGenomics, Inc. (US), Foundation Medicine, Inc. (US), Sequenom, Inc. (US) MDxHealth SA (US), and Chronix Biomedical (US).

Get report sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350

Clinical Microbiology Market Size, Share, Trends and Forecast 2023

According to research report the clinical microbiology market is expected to reach USD 4.95 billion by 2023 from USD 3.63 billion in 2018 growing at a CAGR of 6.4% during forecast period. The technological advancements in the disease diagnostics, rising incidence of infectious diseases and growing outbreak of epidemics, and increased funding and public-private investments in the field of disease diagnosis are the key factors driving the growth of the clinical microbiology market during the forecast period.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=219135367

Strategic analysis of the market developments between 2014 and 2018 revealed that growth strategies such as product launches and enhancements; acquisitions; agreements, partnerships, collaboration; and expansions were adopted by the market players to strengthen their product portfolios and maintain a competitive position in the clinical microbiology market. Among these business strategies, product launches & enhancements and partnerships & collaborations were the two most widely adopted growth strategies.

bioMérieux S.A. (France) held the leading position in the global clinical microbiology market in 2017. The company has a robust product portfolio and a strong geographical presence in more than 150 countries across the world. To maintain its leadership position in the market, the company has been focusing on R&D activities and product launches. In 2017, the company invested ~13% of its revenue in R&D activities, with the aim to improve product quality, accuracy, and reduce the overall throughput time required for a test. The company launched several products in the clinical testing space in the past four years, such as VITEK MS, FilmArray 2.0, VIDAS C. difficile GDH assay kit, GENE-UP diagnostic solution, ChromID Salmonella ELITE, and FilmArray Ebola test, among others. It also aims to increase its geographical presence and strengthen its product portfolio through growth strategies such as partnerships, collaborations, and expansions. In line with this, in 2017, the company established a new R&D center in France, which is a new multidisciplinary R&D center for infectious disease diagnostics. Further, in 2015, the company entered into a distribution agreement with COPAN (Italy), which helped the company to expand its product portfolio.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219135367

Danaher Corporation (US) held the second position in the global clinical microbiology market in 2017. The company operates in the clinical microbiology testing market through its wholly owned subsidiaries— Beckman Coulter and Cepheid. Danaher is focusing on strengthening its position in the global clinical microbiology market mainly by adopting strategies such as acquisitions and new product launches. The acquisition of Beckman Coulter Inc. (a major player in the US life sciences and diagnostics market) in June 2011 helped the company strengthen its product portfolio and increase its share in the clinical microbiology testing market.

The acquisition of Cepheid in November 2016 further helped to enhance the company’s position, expand its molecular diagnostic products portfolio, and increase its market share in the clinical microbiology testing market. The company also acquired Siemens Healthcare’s clinical microbiology business (July 2014) and Xitogen Technologies Inc. (April 2014) to strengthen its product offerings and geographic presence. The company launched several innovative products, such as DxM 6100 Autoplak Advanced System, Xpert Xpress Flu Test Kit, DxONE Clinical Information Management Tools, VERIS Human CMV Assay, and UniCel DxH Connected Workcell Solution, among others. These products have helped the company remain competitive in the microbiology testing market.

Single-use Bioreactors Market Development | Industry Report 2022

According to the new market research report Single-use Bioreactors Market is expected to grow at a CAGR of 21.9% from 2017 to 2022, to reach 2,685.1 Million by 2022 from USD 997.6 Million in 2017. In the current market scenario, there is a growing demand for single-use bioreactor products. The major factors driving the growth of the Single Use Bioreactors include the increasing adoption of SUBs among small companies and startups, reduced automation complexity, ease in cultivating marine organisms, and reduced impact on the environment.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=49113750

The single-use bioreactors market is segmented based on product type, cell type, technology, application, end user, and region.

Based on product type, the market is segmented into monoclonal antibodies, vaccines, gene-modified cells, recombinant proteins, stem cells, and other products (growth factors, interferons, and antisense DNA & RNA). Among the above-mentioned product segments, the stem cells segment is estimated to witness the highest growth during the forecast period. The high growth in this segment can be attributed to advantages such as reduced medium consumption, ease of use, and the ability to monitor process parameters and cell health.

Research & Development is expected to be the Fastest-growing Application Segment in the Single-use Bioreactors Market

Thermo Fisher Scientific, Inc (U.S.) Held the Leadership Position in the SUB in 2014 Owing to Its Broad Product Portfolio and Strong Brand Name

Thermo Fisher Scientific, Inc. will hold the leadership position in the Single Use Bioreactors Market in 2014. The company has an extensive product portfolio, including bioreactors such as open architecture bioreactor systems, turnkey bioreactor systems, and bioreactor accessories. The company has a good reputation and a strong customer base for its SUBs. Sartorius AG holds the second-largest share. It is a leading provider of laboratory equipment and process technologies and has a vast product portfolio that has helped it to maintain its position in the Single Use Bioreactors Market.

The Single Use Bioreactors Market is highly consolidated, with the top five players accounting for a share of more than 75%. The major players include Thermo Fischer Scientific, Inc. (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), GE Healthcare (U.S.), and Pall Corporation (U.S.).

Collaboration is the most preferred strategy adopted by key players in this market. Players adopted this strategy to enhance their product offerings, increase their market share, cater to the customers’ demands, and consolidate their market presence.
The wave-induced motion SUBs and stirred SUBs product segments of this market have emerged as revenue-generating pockets in countries such as the U.S., India, and China.

Get Sample Pages: https://www.marketsandmarkets.com/requestsample.asp?id=49113750

The Europe is expected to account for the largest share of the single-use bioreactors market in 2016. Government support for new biologics has encouraged the research and development of biologics. North America is accounted for the second-largest share of the single-use bioreactors market.
The key players in the single-use bioreactors market are Sartorius Stedim Biotech (France), Merck Millipore (Germany), GE Healthcare (US), Danaher (US), and Thermo Fisher Scientific (US).